APO Research
Talk to an analyst

APO RESEARCH · REPORT

Efavirenz

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Efavirenz Market Outlook and Growth Opportunities 2026

22 December 2025195 pages

Choose your research edition.

Industry ResearchEfavirenz Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Efavirenz Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Efavirenz Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Efavirenz Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Efavirenz Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Efavirenz market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Efavirenz is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Efavirenz market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Efavirenz market include Teva, Mylan, Macleods Pharmaceuticals, Hetero, Cipla, Bristol-Myers Squibb and Aurobindo Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Efavirenz market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Efavirenz and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Efavirenz sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Efavirenz market size, projected growth trends, production technologies, key applications, and end-use industries.

Efavirenz Segment by Company

Teva

Mylan

Macleods Pharmaceuticals

Hetero

Cipla

Bristol-Myers Squibb

Aurobindo Pharma

Efavirenz Segment by Type

Two-drug combination

Three-drug combination

Efavirenz Segment by Application

Adults

Children

Efavirenz Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Efavirenz status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Efavirenz market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Efavirenz significant trends, drivers, influence factors in global and regions.

6. To analyze Efavirenz competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Efavirenz market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Efavirenz and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Efavirenz.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Efavirenz market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Efavirenz industry.

Chapter 3: Detailed analysis of Efavirenz manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Efavirenz in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Efavirenz in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Efavirenz Industry Trends Table 2. Efavirenz Industry Drivers Table 3. Efavirenz Industry Opportunities and Challenges Table 4. Efavirenz Industry Restraints Table 5. Global Efavirenz Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Efavirenz Revenue Share by Company (2021-2026) Table 7. Global Efavirenz Sales Volume by Company (k units) & (2021-2026) Table 8. Global Efavirenz Sales Volume Share by Company (2021-2026) Table 9. Global Efavirenz Average Price (US$/unit) of Company (2021-2026) Table 10. Global Efavirenz Company Ranking, (2024-2026) & (USD Million) Table 11. Global Efavirenz Key Company Manufacturing Base & Headquarters Table 12. Global Efavirenz Company, Product Type & Application Table 13. Global Efavirenz Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Efavirenz by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Two-drug combination Table 18. Significant Companies of Three-drug combination Table 19. Global Efavirenz Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Efavirenz Sales Volume by Type (2021-2026) & (k units) Table 21. Global Efavirenz Sales Volume by Type (2027-2032) & (k units) Table 22. Global Efavirenz Sales Volume Share by Type (2021-2026) Table 23. Global Efavirenz Sales Volume Share by Type (2027-2032) Table 24. Global Efavirenz Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Efavirenz Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Efavirenz Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Efavirenz Sales Value Share by Type (2021-2026) Table 28. Global Efavirenz Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adults Table 30. Significant Companies of Children Table 31. Global Efavirenz Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Efavirenz Sales Volume by Application (2021-2026) & (k units) Table 33. Global Efavirenz Sales Volume by Application (2027-2032) & (k units) Table 34. Global Efavirenz Sales Volume Share by Application (2021-2026) Table 35. Global Efavirenz Sales Volume Share by Application (2027-2032) Table 36. Global Efavirenz Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Efavirenz Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Efavirenz Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Efavirenz Sales Value Share by Application (2021-2026) Table 40. Global Efavirenz Sales Value Share by Application (2027-2032) Table 41. Global Efavirenz Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Efavirenz Sales by Region (2021-2026) & (k units) Table 43. Global Efavirenz Sales Market Share by Region (2021-2026) Table 44. Global Efavirenz Sales by Region (2027-2032) & (k units) Table 45. Global Efavirenz Sales Market Share by Region (2027-2032) Table 46. Global Efavirenz Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Efavirenz Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Efavirenz Sales Value Share by Region (2021-2026) Table 49. Global Efavirenz Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Efavirenz Sales Value Share by Region (2027-2032) Table 51. Global Efavirenz Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Efavirenz Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Efavirenz Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Efavirenz Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Efavirenz Sales by Country (2021-2026) & (k units) Table 56. Global Efavirenz Sales Market Share by Country (2021-2026) Table 57. Global Efavirenz Sales by Country (2027-2032) & (k units) Table 58. Global Efavirenz Sales Market Share by Country (2027-2032) Table 59. Global Efavirenz Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Efavirenz Sales Value Market Share by Country (2021-2026) Table 61. Global Efavirenz Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Efavirenz Sales Value Market Share by Country (2027-2032) Table 63. Teva Company Information Table 64. Teva Business Overview Table 65. Teva Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Teva Efavirenz Product Portfolio Table 67. Teva Recent Development Table 68. Mylan Company Information Table 69. Mylan Business Overview Table 70. Mylan Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Mylan Efavirenz Product Portfolio Table 72. Mylan Recent Development Table 73. Macleods Pharmaceuticals Company Information Table 74. Macleods Pharmaceuticals Business Overview Table 75. Macleods Pharmaceuticals Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Macleods Pharmaceuticals Efavirenz Product Portfolio Table 77. Macleods Pharmaceuticals Recent Development Table 78. Hetero Company Information Table 79. Hetero Business Overview Table 80. Hetero Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Hetero Efavirenz Product Portfolio Table 82. Hetero Recent Development Table 83. Cipla Company Information Table 84. Cipla Business Overview Table 85. Cipla Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Cipla Efavirenz Product Portfolio Table 87. Cipla Recent Development Table 88. Bristol-Myers Squibb Company Information Table 89. Bristol-Myers Squibb Business Overview Table 90. Bristol-Myers Squibb Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Bristol-Myers Squibb Efavirenz Product Portfolio Table 92. Bristol-Myers Squibb Recent Development Table 93. Aurobindo Pharma Company Information Table 94. Aurobindo Pharma Business Overview Table 95. Aurobindo Pharma Efavirenz Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Aurobindo Pharma Efavirenz Product Portfolio Table 97. Aurobindo Pharma Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Efavirenz Distributors List Table 101. Efavirenz Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Efavirenz Product Image Figure 2. Global Efavirenz Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 4. Global Efavirenz Sales (2021-2032) & (k units) Figure 5. Global Efavirenz Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Efavirenz Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Two-drug combination Image Figure 10. Three-drug combination Image Figure 11. Global Efavirenz Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Efavirenz Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Efavirenz Sales Volume Share by Type (2021-2032) Figure 14. Global Efavirenz Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Efavirenz Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Efavirenz Sales Value Share by Type (2021-2032) Figure 17. Adults Image Figure 18. Children Image Figure 19. Global Efavirenz Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Efavirenz Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Efavirenz Sales Volume Share by Application (2021-2032) Figure 22. Global Efavirenz Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Efavirenz Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Efavirenz Sales Value Share by Application (2021-2032) Figure 25. Global Efavirenz Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Efavirenz Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Efavirenz Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Efavirenz Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 30. North America Efavirenz Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Efavirenz Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Efavirenz Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 36. South America Efavirenz Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Efavirenz Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Efavirenz Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Efavirenz Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Efavirenz Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Efavirenz Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Efavirenz Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Efavirenz Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Two-drug combination
  • Three-drug combination
Applications
  • Adults
  • Children
Companies covered
  • Teva
  • Mylan
  • Macleods Pharmaceuticals
  • Hetero
  • Cipla
  • Bristol-Myers Squibb
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Efavirenz Sales Value (2021-2032)
  4. 1.2.2 Global Efavirenz Sales Volume (2021-2032)
  5. 1.2.3 Global Efavirenz Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Efavirenz Market Dynamics
  1. 2.1 Efavirenz Industry Trends
  2. 2.2 Efavirenz Industry Drivers
  3. 2.3 Efavirenz Industry Opportunities and Challenges
  4. 2.4 Efavirenz Industry Restraints
3 Efavirenz Market by Company
  1. 3.1 Global Efavirenz Company Revenue Ranking in 2025
  2. 3.2 Global Efavirenz Revenue by Company (2021-2026)
  3. 3.3 Global Efavirenz Sales Volume by Company (2021-2026)
  4. 3.4 Global Efavirenz Average Price by Company (2021-2026)
  5. 3.5 Global Efavirenz Company Ranking (2024-2026)
  6. 3.6 Global Efavirenz Company Manufacturing Base and Headquarters
  7. 3.7 Global Efavirenz Company Product Type and Application
  8. 3.8 Global Efavirenz Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Efavirenz Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Efavirenz Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Efavirenz Market by Type
  1. 4.1 Efavirenz Type Introduction
  2. 4.1.1 Two-drug combination
  3. 4.1.2 Three-drug combination
  4. 4.2 Global Efavirenz Sales Volume by Type
  5. 4.2.1 Global Efavirenz Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Efavirenz Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Efavirenz Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Efavirenz Sales Value by Type
  9. 4.3.1 Global Efavirenz Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Efavirenz Sales Value by Type (2021-2032)
  11. 4.3.3 Global Efavirenz Sales Value Share by Type (2021-2032)
5 Efavirenz Market by Application
  1. 5.1 Efavirenz Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Children
  4. 5.2 Global Efavirenz Sales Volume by Application
  5. 5.2.1 Global Efavirenz Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Efavirenz Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Efavirenz Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Efavirenz Sales Value by Application
  9. 5.3.1 Global Efavirenz Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Efavirenz Sales Value by Application (2021-2032)
  11. 5.3.3 Global Efavirenz Sales Value Share by Application (2021-2032)
6 Efavirenz Regional Sales and Value Analysis
  1. 6.1 Global Efavirenz Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Efavirenz Sales by Region (2021-2032)
  3. 6.2.1 Global Efavirenz Sales by Region: 2021-2026
  4. 6.2.2 Global Efavirenz Sales by Region (2027-2032)
  5. 6.3 Global Efavirenz Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Efavirenz Sales Value by Region (2021-2032)
  7. 6.4.1 Global Efavirenz Sales Value by Region: 2021-2026
  8. 6.4.2 Global Efavirenz Sales Value by Region (2027-2032)
  9. 6.5 Global Efavirenz Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Efavirenz Sales Value (2021-2032)
  12. 6.6.2 North America Efavirenz Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Efavirenz Sales Value (2021-2032)
  15. 6.7.2 Europe Efavirenz Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Efavirenz Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Efavirenz Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Efavirenz Sales Value (2021-2032)
  21. 6.9.2 South America Efavirenz Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Efavirenz Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Efavirenz Sales Value Share by Country, 2025 VS 2032
7 Efavirenz Country-level Sales and Value Analysis
  1. 7.1 Global Efavirenz Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Efavirenz Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Efavirenz Sales by Country (2021-2032)
  4. 7.3.1 Global Efavirenz Sales by Country (2021-2026)
  5. 7.3.2 Global Efavirenz Sales by Country (2027-2032)
  6. 7.4 Global Efavirenz Sales Value by Country (2021-2032)
  7. 7.4.1 Global Efavirenz Sales Value by Country (2021-2026)
  8. 7.4.2 Global Efavirenz Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Efavirenz Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Efavirenz Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Efavirenz Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Efavirenz Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Efavirenz Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Efavirenz Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Efavirenz Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Efavirenz Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Efavirenz Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Efavirenz Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Efavirenz Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Efavirenz Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Efavirenz Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Efavirenz Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Efavirenz Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Efavirenz Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Efavirenz Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Efavirenz Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Efavirenz Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Efavirenz Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Efavirenz Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Efavirenz Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Efavirenz Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Efavirenz Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Efavirenz Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Efavirenz Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Efavirenz Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Efavirenz Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Efavirenz Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Efavirenz Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Efavirenz Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Efavirenz Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Efavirenz Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Efavirenz Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Efavirenz Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Efavirenz Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Efavirenz Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Efavirenz Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Efavirenz Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Efavirenz Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Efavirenz Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Efavirenz Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Efavirenz Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Efavirenz Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Efavirenz Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Efavirenz Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Efavirenz Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Efavirenz Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Efavirenz Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Efavirenz Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Efavirenz Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Efavirenz Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Efavirenz Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Efavirenz Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Efavirenz Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Efavirenz Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Efavirenz Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Efavirenz Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Efavirenz Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Efavirenz Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Efavirenz Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Efavirenz Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Efavirenz Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Efavirenz Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Efavirenz Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Efavirenz Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Efavirenz Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Efavirenz Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Efavirenz Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Efavirenz Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Efavirenz Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Efavirenz Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Efavirenz Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Efavirenz Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Efavirenz Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Efavirenz Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Efavirenz Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Efavirenz Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Efavirenz Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Efavirenz Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Efavirenz Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Efavirenz Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Efavirenz Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Efavirenz Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Efavirenz Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Efavirenz Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Mylan
  8. 8.2.1 Mylan Company Information
  9. 8.2.2 Mylan Business Overview
  10. 8.2.3 Mylan Efavirenz Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Mylan Efavirenz Product Portfolio
  12. 8.2.5 Mylan Recent Developments
  13. 8.3 Macleods Pharmaceuticals
  14. 8.3.1 Macleods Pharmaceuticals Company Information
  15. 8.3.2 Macleods Pharmaceuticals Business Overview
  16. 8.3.3 Macleods Pharmaceuticals Efavirenz Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Macleods Pharmaceuticals Efavirenz Product Portfolio
  18. 8.3.5 Macleods Pharmaceuticals Recent Developments
  19. 8.4 Hetero
  20. 8.4.1 Hetero Company Information
  21. 8.4.2 Hetero Business Overview
  22. 8.4.3 Hetero Efavirenz Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hetero Efavirenz Product Portfolio
  24. 8.4.5 Hetero Recent Developments
  25. 8.5 Cipla
  26. 8.5.1 Cipla Company Information
  27. 8.5.2 Cipla Business Overview
  28. 8.5.3 Cipla Efavirenz Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Cipla Efavirenz Product Portfolio
  30. 8.5.5 Cipla Recent Developments
  31. 8.6 Bristol-Myers Squibb
  32. 8.6.1 Bristol-Myers Squibb Company Information
  33. 8.6.2 Bristol-Myers Squibb Business Overview
  34. 8.6.3 Bristol-Myers Squibb Efavirenz Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bristol-Myers Squibb Efavirenz Product Portfolio
  36. 8.6.5 Bristol-Myers Squibb Recent Developments
  37. 8.7 Aurobindo Pharma
  38. 8.7.1 Aurobindo Pharma Company Information
  39. 8.7.2 Aurobindo Pharma Business Overview
  40. 8.7.3 Aurobindo Pharma Efavirenz Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aurobindo Pharma Efavirenz Product Portfolio
  42. 8.7.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Efavirenz Value Chain Analysis
  2. 9.1.1 Efavirenz Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Efavirenz Sales Mode & Process
  6. 9.2 Efavirenz Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Efavirenz Distributors
  9. 9.2.3 Efavirenz Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst